Company: IMRX
Filing Date: 2025-08-25
Form Type: 8-K
Source: 0001104659-25-081995
Chunk: 2

Company: Immuneering Corp
Filing Date: 2025-08-25
Form: 8-K
Item: Item 1.01
Chunk 2
---
 with the terms of such warrant, which percentage may be increased at the holder’s election upon 61 days’ notice
to the Company subject to the terms of such warrants, provided that such percentage may in no event exceed 9.99% (the “ Beneficial
Ownership Limitation”).

On August 21, 2025, in connection with the Purchase Agreement, the
Company entered into a Registration Rights Agreement (the “ Registration Rights Agreement”) with all of the Investors. Pursuant
to the Registration Rights Agreement, the Company agreed to prepare and file a registration statement with the Securities and Exchange
Commission (the “ SEC”) within 30 days after the Closing Date, for purposes of registering the resale of the Shares and the
shares of Common Stock issuable upon exercise of the Pre-Funded Warrants and Purchase Warrants (the “ Warrant Shares”) purchased
by the Investors in the Private Placement, and any shares of Common Stock issued as a dividend or other distribution with respect to,
in exchange for or in replacement of such Shares or Warrant Shares. The Company agreed to use commercially reasonable efforts to cause
such registration statement to be declared effective by the SEC within 60 days after the Closing Date, or 90 days after the Closing Date
if the SEC reviews the registration statement.

The Company has also agreed to, among other things, indemnify each
Investor, its officers, directors, members, managers, partners, trustees, employees and agents and other representatives, successors and
assigns, and each other person, if any, who controls such Investor within the meaning of the Securities Act, under the registration statement
against certain liabilities incident to the Company’s obligations under the Registration Rights Agreement.

The Private Placement is exempt from registration pursuant to Section
4(a)(2) of the Securities Act and Regulation D promulgated thereunder, as a transaction by an issuer not involving a public offering.
The Investors have not acquired the securities with a view to or for sale in connection with any distribution thereof in violation of
the Securities Act and appropriate legends have been affixed to the securities issued in this transaction.

The foregoing summaries do not purport to be complete and are qualified
in their entirety by reference to the Purchase Agreement, the Registration Rights Agreement, the Pre-Funded Warrants and the Purchase
Warrants, which are filed as Exhibits 10.1, 10.2, 4.1 and 4.2, respectively, to this Current Report on Form 8-K.

Item